This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling

计划入组 60 人 · 首次发布于 2026 年 1 月 7 日

ALKBH5(HOIST)

ALKBH5 modulator (glioblastoma)

ALKBH5-target therapeutics(RPXDS)

Comprehensive Review Reveals Therapeutic Potential of m6A Regulatory Protein Inhibitors in Cancer Treatment

Agomab Unveils Design for First-Ever Phase 2b Trial in Fibrostenosing Crohn's Disease with Oral ALK5 Inhibitor Ontunisertib